FlandersBio on Twitter

Follow us on Twitter

Archive for January 2013 - News

Archive for January 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Cryo-Save Group N.V. - Share buyback tranche successfully completed

31.01.2013

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has completed the tranche of its share buyback programme as announced on 30 January 2013. read more

Cryo-Save launches Africa’s most state-of-the-art cryogenic storage laboratory

31.01.2013

Today, Cryo-Save opens the doors to their state-of-the-art laboratory in Pretoria, the executive capital of South Africa. The newly built laboratory is the most modern facility of its kind in the whole of Africa, and is the largest stem cell storage facility on the continent. It replaces the Cape Town lab. Cryo-Save is the leading family stem cell bank storing more than 225,000 stem cell samples from umbilical cord blood and umbilical cord tissue. read more

Cryo-Save Group N.V. - Buyback of shares

30.01.2013

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has commenced a new tranche of its share buyback programme. read more

Galapagos receives €2.5 million IWT grant for IBD research

30.01.2013

Galapagos NV (Euronext: GLPG) announced today that it has been awarded a €2.5 million grant from the Flemish agency for Innovation by Science and Technology (IWT) for inflammatory bowel disease (IBD) research and development. The goal of this 2.5-year project is to identify new therapeutic compounds for future treatment of IBD patients. read more

TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid

29.01.2013

TiGenix (Euronext Brussels: TIG), a leader in the field of cell therapy, announced today that further to the cGMP inspection by the Spanish health authorities it has successfully renewed its manufacturing authorization for stem cell products at its manufacturing facility in Madrid, Spain. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print